PT  - JOURNAL ARTICLE
AU  - Gazit, Sivan
AU  - Mizrahi, Barak
AU  - Kalkstein, Nir
AU  - Neuberger, Ami
AU  - Peretz, Asaf
AU  - Mizrahi-Reuveni, Miri
AU  - Patalon, Tal
TI  - BNT162b2 mRNA Vaccine Effectiveness Given Confirmed Exposure; Analysis of Household Members of COVID-19 Patients
AID  - 10.1101/2021.06.29.21259579
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.29.21259579
4099  - http://medrxiv.org/content/early/2021/07/03/2021.06.29.21259579.short
4100  - http://medrxiv.org/content/early/2021/07/03/2021.06.29.21259579.full
AB  - Importance While the mRNA BNT162b2 vaccine effectivness was demonstrated in general population, the question of effectiveness given confirmed exposure has yet been answered, though it has policy implications, as the need for self-quarantine when exposed and protective measures for vaccinated in high-risk areas.Objective Assessing the BNT162b2 vaccine effectiveness in preventing SARS-CoV-2 infection given high-risk exposure, through analysis of household members of confirmed cases.Design Retrospective cohort study. Data of household members of confirmed SARS-CoV-2 cases between 20/12/2020 and 17/03/2021 were collected.Setting Nationally centralized database of Maccabi Healthcare Services (MHS), the second largest Healthcare Maintenance Organization in Israel.Participants 2.5 million MHS members were considered, of which we included only households with two adult members, given possible lower transmission and susceptibility among children. Households with no prior confirmed infections and a confirmed index case during the study period were included.Exposure Participants were classified into three vaccination groups in time of the index case (the confirmed exposure)-Unvaccinated; Fully Vaccinated(7 or more days post second dose) and a reference control group of Recently Vaccinated Once(0-7 days from the first dose, presumably still unprotected).Main Outcomes and Measures Assessing the probability of an additional SARS-CoV-2 infection in the household occurring within 10 days of an index case, calculated separately for the three vaccination groups. Main outcome was vaccine effectiveness given confirmed exposure. High testing rates among household members enabled us to estimate with a high degree of confidence effectiveness against asymptomatic SARS-CoV-2 infection as well.Results A total of 173,569 households were included, out of which 6,351 households had an index infection (mean [SD] age, 58.9 [13.5] years; 50% were women). Vaccine effectiveness of Fully Vaccinated compared to Unvaccinated participants was 80.0% [95% CI, 73.0-85.1] and 82.0% [95% CI, 75.5-86.7] compared to those Recently Vaccinated Once.Conclusion and Relevance The BNT162b2 vaccine is effective in a high-risk, real life, exposure scenario, but the protection rates afforded in these settings are lower than those previously described. Household members of COVID-19 patients and any individual with a confirmed exposure to COVID-19 are still at a considerable risk of being infected even if fully vaccinated.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere was no external funding for the project.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Maccabi Healthcare Services (MHS) Institutional Review Board (033-21-MHS). Informed consent was waived by the Maccabi Healthcare Services Institutional Review Board (IRB) as all identifying details of the participants were removed before computational analyses.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAccording to the Israel Ministry of Health regulations, individual-level data cannot be shared openly. Specific requests for remote access to de-identified data should be referred to KSM Research and Innovation Center, Maccabi Healthcare Services.